A

Amgen

Biotech company creating biologic medicines

Competitive Intelligence Senior Manager - Global Biosimilars

Full-TimeUpdated on 10/5/2026
$155.7k - $210.7k+ Annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, MBA, PhD, Associate's
Thousand Oaks, CA, USA
HybridFlex commuter arrangement; at least one on-site day per month is highly encouraged.

About the job

Requirements
  • A doctorate degree and 2 years of competitive intelligence or similar experience; or a master's degree and 4 years; or a bachelor's degree and 6 years; or an associate's degree and 10 years; or a high school diploma or GED and 12 years.
  • Knowledge of basic principles across the pharmaceutical value chain, including drug discovery and development, clinical trials, FDA and EMA regulation, and drug commercialization.
  • Experience managing multiple simultaneous projects and working with proprietary technical, regulatory, and financial data sources such as TrialTrove, Cortellis Intelligence, Evaluate Pharma, and PubMed.
  • Experience supporting insight generation with cross-functional commercial, medical, and scientific teams to develop therapeutic-area strategy.
  • Ability to analyze ongoing clinical trials and global regulatory considerations to develop competitor launch-timing scenarios in the United States, European Union, Japan, China, and other key markets.
  • Understanding of pharmaceutical forecasting models and ability to provide competitor-focused assumptions to estimate market share for long-range planning scenarios, go/no-go decisions, and business-development opportunity assessment.
  • Advanced degree (PhD, MS, or MBA) focused on life sciences or business.
  • Five years of hands-on experience in biosimilars or biologics competitive intelligence, strategy, or management consulting.
  • Expertise applying large language model-based text mining, retrieval-augmented generation, or dashboarding within competitive or market intelligence.
  • Project leadership and vendor-management capabilities in fast-moving, matrixed environments.
Responsibilities
  • Lead competitive-intelligence strategy for biosimilars strategic pipeline assets as the primary thought partner to the Biosimilars Business Unit; own asset/brand-, therapeutic-area-, and company-level intelligence, develop deep competitor expertise, and translate insights into actionable recommendations for business decisions.
  • Lead the full competitive-intelligence cycle by defining Key Intelligence Topics and Questions with Marketing and other business colleagues, executing hypothesis-driven primary and secondary research, and delivering actionable insight packages to internal stakeholders.
  • Leverage and expand AI-enabled technologies, including Codex, generative AI, natural language processing, predictive analytics, and automation, to improve competitive-intelligence workflows, accelerate signal detection, and raise insight quality.
  • Integrate key opinion leader and investigator interviews, conference intelligence, and clinical-trial and market databases—including ClinicalTrials.gov, TrialTrove, BioMedTracker, Evaluate, Cortellis, FactSet, and AlphaSense—into competitive landscapes and scenario plans.
  • Direct and mentor external vendors and internal partners to execute research, facilitate red-team and war-gaming simulations, and lead rapid-response congress debriefs.
  • Present strategic recommendations to senior leadership, champion competitive-intelligence best practices, ensure compliance with legal and ethical competitive-intelligence standards, nurture talent, and contribute to enterprise AI and analytics forums.
Desired Qualifications
  • Excellent storytelling skills to distill complex scientific and commercial data for executive audiences.
  • High learning agility, intellectual curiosity, and a collaborative mindset.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
  • Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
  • Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.

What critics are saying

  • Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
  • Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
  • MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.

What makes Amgen unique

  • September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
  • August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
  • MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.